Literature DB >> 1336527

Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial.

A J Palmer1, A E Fletcher, P J Rudge, C D Andrews, T S Callaghan, C J Bulpitt.   

Abstract

AIM: To compare the effects of captopril and atenolol on quality of life of hypertensive patients.
METHODS: In a randomly allocated double-blind crossover trial with two 6-week treatment periods captopril at 25 mg twice a day or atenolol at 50 mg once a day were administered to 265 hypertensive patients (mean age 56 years; 55% men). Of these, 65% were newly treated hypertensives and 35% were previously uncontrolled on a diuretic alone. A seated diastolic blood pressure of 95-115 mmHg was required after a 3-week placebo run-in period. Any previous diuretic therapy was changed to hydrochlorothiazide (25 mg once a day) and the dose was kept constant throughout the trial. Newly diagnosed patients did not take a diuretic at any time. Quality of life was assessed from self-completed questionnaires measuring psychological well-being, symptomatic side effects of treatment, and activity and perceived well-being (a health index). A relative's perception of the patients' mood was also obtained where possible.
RESULTS: Twelve patients withdrew on atenolol and 10 on captopril. No differences between the drugs were observed in quality of life measures, and 95% confidence intervals suggested that important differences were excluded.
CONCLUSION: We conclude that at the doses used in this trial there were no important differences between captopril and atenolol in their effects on quality of life.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336527     DOI: 10.1097/00004872-199211000-00014

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  11 in total

Review 1.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 2.  Quality-of-life instruments in hypertension.

Authors:  C J Bulpitt; A E Fletcher
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 3.  The effects of ACE inhibitors on cognitive function.

Authors:  A A O'Brien; C J Bulpitt
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

4.  Quality of life is not negatively affected by diet and exercise intervention in healthy men with cardiovascular risk factors.

Authors:  M L Hellénius; C Dahlöf; H Aberg; I Krakau; U de Faire
Journal:  Qual Life Res       Date:  1995-02       Impact factor: 4.147

Review 5.  A risk-benefit analysis for the treatment of hypertension.

Authors:  C J Bulpitt
Journal:  Postgrad Med J       Date:  1993-10       Impact factor: 2.401

6.  Treating hypertension. Are the right drugs given to the right patients?

Authors:  M D Beaulieu; L Dufresne; D LeBlanc
Journal:  Can Fam Physician       Date:  1998-02       Impact factor: 3.275

Review 7.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.

Authors:  Alain J Nordmann; Murray Krahn; Alexander G Logan; Gary Naglie; Allan S Detsky
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 9.  Epidemiology of stroke. Importance of preventive pharmacological strategies in elderly patients and associated costs.

Authors:  I Kawachi
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

10.  Health-related quality of life and blood pressure control in hypertensive patients with and without complications.

Authors:  Josiane Lima de Gusmão; Decio Mion; Angela Maria Geraldo Pierin
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.